Clinical trials: Monoclonal Antibody
Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05186909
- Testing
- CM310
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Keymed Biosciences Co.Ltd
Neoplasms
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
The Primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers…
- Trial name
- NCT02908906
- Testing
- JNJ-63723283
- Where
- 20 sites in United States, Moldova and 5 more
- Volunteers
- 234 people
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis
Tanezumab In Osteoarthritis Of The Hip Or Knee
The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis
- Trial name
- NCT00985621
- Testing
- tanezumab 10 mg, tanezumab 5 mg, oxycodone
- Where
- 112 sites in United States, Austria and 5 more
- Volunteers
- 614 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small cell lung cancer.
- Trial name
- CLASSICAL-Lung (NCT03268057)
- Testing
- VX15/2503 + avelumab
- Where
- 11 sites in United States
- Volunteers
- 62 people
- Sponsor
- Vaccinex Inc.
Pancreatic Ductal Adenocarcinoma, PDAC
Influence Factors of PD-1 Therapeutic Efficacy in Advanced Pancreatic Cancer
The early diagnosis rate of pancreatic cancer is low and most patients rely on palliative chemotherapy. However, the clinical benefit and objective response rate (ORR) of patients with first-line chemotherapy are low.
- Trial name
- NCT05201729
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
T-LGL Lymphoproliferative Disorders
Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia
This study will examine the use of alemtuzumab (Campath) in patients with T cell large granular lymphocytic leukemia (T-LGL). Patients with T-LGL often have reduced white blood cells, red blood cells and platelets, and increased…
- Trial name
- NCT00345345
- Testing
- Alemtuzumab (Campath)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them. PURPOSE: Randomized phase II trial to determine the effectiveness of monoclonal antibody therapy in…
- Trial name
- NCT00019539
- Testing
- bevacizumab, thalidomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma…
- Trial name
- NCT00719212
- Testing
- AMG 479
- Where
- 37 sites in United States, Canada and 5 more
- Volunteers
- 61 people
- Sponsor
- Translational Research in Oncology
Advanced Hepatocellular Carcinoma (HCC)
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
This study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody, anti-VEGFR monoclonal antibody and TACE regimen for the treatment of patients…
- Trial name
- NCT06995105
- Testing
- TACE, Sintilimab combined with Bevacizumab, individualized anti-tumor new antigen iNeo-Vac-R01 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Axial Spondyloarthritis
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis
The aim of the study is to evaluate the efficacy, safety, immunogenicity, pharmacokinetics and pharmacodynamics of two doses of study drug (BCD-180) in comparison with placebo in patients with active radiographic axial…
- Trial name
- ELEFTA (NCT05445076)
- Testing
- anti-TRBV9 monoclonal antibody, low dose, anti-TRBV9 monoclonal antibody, high dose
- Where
- 2 sites in Russia
- Volunteers
- 250 people
- Sponsor
- Biocad
Lymphoma
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic imaging procedures, such as radiolabeled monoclonal antibodies, may improve the ability to detect the residual disease in patients who have been treated for non-Hodgkin's lymphoma.
- Trial name
- NCT00003338
- Testing
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Where
- 8 sites in United States, Austria and 3 more
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Hepatocellular Carcinoma, Hepatitis C Virus Chronic Infection
Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma
CP-675,206 (tremelimumab) is a fully humanized monoclonal antibody that binds to activated T lymphocytes and by enhancing their activation may produce a stimulation of the immune response against tumoral or viral antigens.
- Trial name
- NCT01008358
- Testing
- CP 675,206
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Breast Cancer
Radiolabeled Monoclonal Antibody Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00007891
- Testing
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 2 sites in United States
- Sponsor
- Cancer Research Institute of Contra Costa
Solid Tumors
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
This is an open label, dose escalation study to evaluate the safety and tolerability of KN035 in advanced and metastatic solid tumor.
- Trial name
- NCT02827968
- Testing
- KN035
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Psoriasis
Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis
CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira® when used in patients with…
- Trial name
- CALYPSO (NCT02762955)
- Testing
- BCD-057, Humira®
- Where
- Russia
- Volunteers
- 344 people
- Sponsor
- Biocad
Prostate Cancer
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body.
- Trial name
- NCT00061126
- Testing
- ABX-EGF
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Abgenix
Rheumatoid Arthritis
Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis
This study will assess the long-term safety and tolerability of ACZ885 in patients with rheumatoid arthritis, as well as long-term efficacy, long-term preservation and/or improvement of joint structure and bone mineral density…
- Trial name
- NCT00554606
- Testing
- Canakinumab
- Where
- 51 sites in United States, Belgium and 7 more
- Volunteers
- 115 people
- Sponsor
- Novartis
Hodgkin's Disease
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
The purpose of this study is to find the highest safe dose of Iodine-131 Tositumomab (Bexxar®) that can be given to patients who have relapsed/refractory Hodgkin's lymphoma, what side effects these patients get when they take…
- Trial name
- NCT00484874
- Testing
- I-131 Tositumomab therapeutic regimen
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00003150
- Testing
- rituximab, CHOP regimen, cyclophosphamide
- Where
- 91 sites in United States
- Volunteers
- 630 people
- Sponsor
- Eastern Cooperative Oncology Group
Treatment for Advanced Colorectal Cancer, Treatment for Advanced Pancreatic Cancer
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies
- Trial name
- NCT07446270
- Testing
- Colorectal cancer: Tunlametinib + cetuximab β, Pancreatic cancer: Tunlametinib + cetuximab β, Pancreatic cancer: Tunlametinib +Nimotuzumab
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.